RVP - Retractable Tech P/S Multiple

Corporate company logo of retractable.com (RVP)

The absence of M&A deals for decades may seem like stagnation, yet the P/S ratio of Retractable Technologies (RVP) demonstrates a different trend, where the parameter stands at 0.50. Stability is maintained through a strong engineering staff and rigorous quality control. Confidence is further bolstered by US government contracts for the supply of retractable syringes designed to protect healthcare workers from injuries.

RVP Retractable Technologies: P/S Multiple in the range 07/04/2022 - 11/13/2026

Retractable Technologies (RVP) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Fundamental company analysis:RVP, Retractable Technologies Inc.
Manufactured products of Retractable Tech

Amid aggressive price dumping in the medical syringe market, the price-to-sales ratio on the GURU.Markets platform reflects the market value of a single unit of sales for Retractable Technologies (RVP). This multiple compares the current market capitalization of Retractable Technologies (RVP) with the volume of generated revenue to determine the degree of business overvaluation. This price action captures investor reactions to pressure from consolidated healthcare systems, while sharp fluctuations in the indicator signal a shift in the fundamental valuation of the company's growth prospects.

Competitors of Retractable Technologies

ISRG (intuitive.com) - Market Capitalization-to-Revenue Ratio|Danaher - Market Cap to Revenue|P/S Multiple BD BDX|STE - Price-to-Revenue Ratio|West Pharma Corp (WST) - Market Cap to Revenue|BAX: P/S Multiple|Price to Sales masimo.com (MASI)|Price-to-Revenue Ratio Stevanato Group|Market Cap to Revenue Ratio TFX (Teleflex Inc.)|Market Cap to Revenue MMSI (Merit Medical Systems Inc)|Market Cap to Sales Volume NVST|Price-to-Revenue Ratio ICU Medical, Inc. ICUI|Price-to-Revenue Coefficient dentsplysirona.com (XRAY)|LMAT - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ATRC (AtriCure Inc)|STAA: P/S Multiple|Price to Sales Niagen (NAGE)|Market Cap to Revenue ZIMV|ANGO (angiodynamics.com) - Market Cap to Sales Volume|Price-to-Revenue Ratio Cerus (CERS)|TKNO (Alpha Teknova) - Market Capitalization-to-Revenue Ratio|P/S Multiple MGRM (Monogram Technologies Inc)|P/S Multiple Sharps Technology Inc STSS|InfuSystem Inc - P/S Multiple|utahmed.com (UTMD) - Market Cap to Revenue|KRMD (korumedical.com) - Market Cap to Revenue|NYXH: Market Cap to Sales Volume|MBOT (Microbot Medical Inc) - P/S Multiple|P/S Multiple Pro-Dex Inc.|P/S Multiple ZTEK|Price-to-Revenue Ratio ELUT (elutia.com)|Price-to-Revenue Ratio Milestone Scientific Inc. MLSS|NEXGEL Inc. - Price-to-Revenue Ratio|Harvard Bioscience - P/S Multiple|Price to Sales Femasys Corporation|MHUA (meihuamed.com) - Market Cap to Revenue|Predictive Oncology Inc. - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CJMB|ATRI (Atrion Corp.) - Market Cap to Sales Volume|P/S Multiple NURO